<DOC>
	<DOCNO>NCT01869023</DOCNO>
	<brief_summary>Malignant pleural mesothelioma ( MPM ) rare disease , high mortality . MPM frequently find advanced stage . The standard treatment advance pleural mesothelioma cisplatin-based chemotherapy combine pemetrexed/raltitrexed ( phase III study show benefit response overall survival compare cisplatin alone ) . There active drug liposomal doxorubicin gemcitabine . Unfortunately , cost important factor consider population standard treatment expensive . Gemcitabine 250 mg infuse 6 hrs combination cisplatin , compare standard administration gemcitabine 1250 mg infusion 30 minute NSCLC , combine cisplatin show 75 mg show study equally effective treat cancer non-small cell lung . A phase II study use strategy advance MPM show promising result . Gemcitabine administer low dose six hour infusion may reduce cost treatment without alter effectiveness . Primary Objective . -Evaluate response treatment gemcitabine dose 250 mg/m2SC 6-hour infusion combine cisplatin patient unresectable malignant mesothelioma . Secondary objective . - Evaluate toxicity combination gemcitabine dose 250 mg/m2 infuse 6 hour cisplatin patient unresectable malignant mesothelioma . - Evaluate progression free survival ( PFS ) overall survival ( OS ) patient unresectable MM treat combination . Hypothesis : Combination therapy gemcitabine dose 250 mg/m2 infusion 6 hr apply day 1 8 combine cisplatin 35 mg/m2SC apply day 1 3 week cycle treatment provide similar result response compare previous study combination therapy , conventional administration ( gemcitabine 1,250 mg 30 minute day 1 , 8 15 ) .</brief_summary>
	<brief_title>Phase II Study Six Hours Low Dose Gemcitabine Plus Cisplatin Treatment Advanced Pleural Mesothelioma</brief_title>
	<detailed_description>Malignant pleural mesothelioma rare disease , high mortality . It usually develop people expose asbestos , latency period range 20 40 year . Most patient present advanced disease , consider unresectable combination chemotherapy treatment choice . Currently standard treatment combination pemetrexed cispaltin , treatment show benefit overall survival overall response rate comparison treatment cisplatin alone . This standard chemotherapy country difficult access due cost treatment poor economic situation patient . That 's determine effectiveness treatment option show activity disease less expensive , vital importance country . Phase I study gemcitabine show maximum tolerate dose varies time infusion , 250 mg/m2 maximum tolerate dose infusion carry 6 hour , opposed 1250 mg/m2 gemcitabine administer conventional manner . A phase III study NSCLC , compare administration gemcitabine infusion 250 mg/m2 6 hour versus conventional administration 1,250 mg/m2 30 minute show treatment similar efficacy toxicity . The group conduct phase II study unresectable malignant pleural mesothelioma publish recently promising result . That decide conduct phase II study patient unresectable malignant pleural mesothelioma idea validate result previously obtain study factor associate resistance chemotherapy ERCC1 , RPM1 , thymidylate synthase .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologic Diagnosis Pleural Mesothelioma Multidisciplinary assessment consider candidate resection . Karnofsky &gt; = 70 ECOG &lt; 2 Adequate Hematologic , renal hepatic function . Superior vena cava syndrome , severe bone pain CNS metastasis Not candidate chemotherapy ( Poor functional status : ECOG &gt; 2 ) The patient refuse participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Malignant Pleural Mesothelioma</keyword>
	<keyword>Gemcitabine cisplatin</keyword>
	<keyword>Gemcitabine continuous infusion</keyword>
</DOC>